© 2023 MJH Life Sciences and CGTLive™. All rights reserved.
© 2023 MJH Life Sciences™ and CGTLive™. All rights reserved.
No adverse events related to the infusions of stromal cells were reported.
The phase 1 portion of the trial assessing CNA3103 will start enrollment in Australia in the first half of 2023; the phase 2 portion will expand to the US.
Cilta-cel demonstrated a significant improvement in progression-free survival over standards of care.